Table of Content


Introduction
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Overview
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021


List of Tables


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Indications, 2021 (Contd..3)
Number of Products under Development by Indications, 2021 (Contd..4)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Adastra Pharmaceuticals Inc, 2021
Pipeline by Aerie Pharmaceuticals Inc, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Celon Pharma SA, 2021
Pipeline by Concert Pharmaceuticals Inc, 2021
Pipeline by CTI BioPharma Corp, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2021
Pipeline by HK inno.N Corp, 2021
Pipeline by Incyte Corp, 2021
Pipeline by Japan Tobacco Inc, 2021
Pipeline by Jiangsu Simcere Pharmaceutical Co Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by NS Pharma Inc, 2021
Pipeline by OHM Oncology, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2021
Pipeline by Sierra Oncology Inc, 2021
Pipeline by Sino Biopharmaceutical Ltd, 2021
Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2021
Pipeline by Theravance Biopharma Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Dormant Products, 2021 (Contd..4)
Dormant Products, 2021 (Contd..5)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)